MSD in the UK Integrates Vaccines Portfolio into new Business Unit
Focused on Prevention and Public Health

HODDESDON, Tuesday 3rd January 2017 – Today MSD (Merck & Co., Inc., Kenilworth, NJ, USA in the United States and Canada) integrates its vaccines and women’s health portfolios into a new business unit focused on prevention and public health. Along with 18 European countries, MSD in the UK will now independently manage the broad vaccine portfolio of childhood, adolescent and adult vaccines, and pursue its own distinct growth strategies following the end of the joint venture with Sanofi Pasteur, called SPMSD (Sanofi Pasteur MSD), at the end of 2016.

Committed to driving growth and optimising vaccine coverage to help protect lives globally and in the UK, MSD is proud to continue to build on the considerable success Sanofi Pasteur MSD Limited, to be renamed MSD Vaccines Ltd, has achieved over the past two decades from a public health and commercial perspective.

“The integration of the vaccines portfolio into our newly formed business unit focused on prevention and public health represents our deepening commitment to helping the NHS enable every child, woman and man to have a healthier future. Our vaccines portfolio helps protect children, adolescents and adults from a number of diseases, including the prevention of once common diseases, like measles and mumps, to diseases never thought preventable, like shingles and cervical cancer,” said Louise Houson, Managing Director for the UK & Ireland. “This marks a significant step forward in our mission to transform healthcare through innovative solutions that save and improve lives. We will be working hard to ensure as smooth a transition as possible to deliver great value to all of our stakeholders.”

For more than 100 years, MSD has played an important and defining role in the history of vaccines. Today MSD provides more than 150 million doses of vaccines¹ around the world every year. MSD also researches potential solutions to address critical global health needs. During the
wake of Ebola epidemic in 2014, MSD stepped in and developed an investigational Ebola vaccine, V920 (rVSVΔG-ZEBOV-GP live attenuated), and received Priority Medicines (PRIME) status from the European Medicines Agency (EMA) in 2016\(^2\). Including V920, MSD has extensive candidates in the pipeline exploring ways to ensure people everywhere have the access to the protection they need\(^3\).

**About MSD**
For 125 years, MSD has been a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., Kenilworth, NJ., USA. Through our prescription medicines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships. For more information, visit www.msd-uk.com.

**Notes to editors (for GP media only):**
For customer information about supply and distribution within the UK and for all future orders after 3rd January 2017, customers can call the MSD wholesaler, AAH, Customer Services team on 0844 561 2008. Customers can view stock availability on the AAH website: www.aah.co.uk.

**For further information please contact:**
Name: Meral Nugent
Tel: 01992 452358
Mob: 07779 706558
Meral.nugent@merck.com

Name: Gurjit Hothi
Tel: 020 7009 3812
Mob: 07984 160636
Gurjit.hothi@3monkeyszeno.com

**References**
\(^1\) MSD Data on File
\(^2\) MSD Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920). Available here [Last accessed December 2016]
\(^3\) MSD Pipeline. Available here [Last accessed December 2016]